SG11201507424WA - Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor - Google Patents
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptorInfo
- Publication number
- SG11201507424WA SG11201507424WA SG11201507424WA SG11201507424WA SG11201507424WA SG 11201507424W A SG11201507424W A SG 11201507424WA SG 11201507424W A SG11201507424W A SG 11201507424WA SG 11201507424W A SG11201507424W A SG 11201507424WA SG 11201507424W A SG11201507424W A SG 11201507424WA
- Authority
- SG
- Singapore
- Prior art keywords
- immunoreactive
- express
- effector cells
- immune effector
- bispecific molecules
- Prior art date
Links
- 230000003213 activating effect Effects 0.000 title 1
- 239000012642 immune effector Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361783195P | 2013-03-14 | 2013-03-14 | |
PCT/US2014/025491 WO2014159940A1 (en) | 2013-03-14 | 2014-03-13 | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201507424WA true SG11201507424WA (en) | 2015-10-29 |
Family
ID=51625295
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201507424WA SG11201507424WA (en) | 2013-03-14 | 2014-03-13 | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
SG10201705245TA SG10201705245TA (en) | 2013-03-14 | 2014-03-13 | Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201705245TA SG10201705245TA (en) | 2013-03-14 | 2014-03-13 | Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof |
Country Status (25)
Country | Link |
---|---|
US (4) | US9908938B2 (en) |
EP (2) | EP3839044A1 (en) |
JP (3) | JP6676521B2 (en) |
CN (2) | CN111925437A (en) |
AP (1) | AP2015008740A0 (en) |
AU (2) | AU2014244286B2 (en) |
BR (1) | BR112015022790A8 (en) |
CA (1) | CA2906566A1 (en) |
CY (1) | CY1124570T1 (en) |
DK (1) | DK2968520T3 (en) |
ES (1) | ES2882183T3 (en) |
HK (1) | HK1219876A1 (en) |
HR (1) | HRP20211212T1 (en) |
HU (1) | HUE055845T2 (en) |
IL (2) | IL241487B (en) |
LT (1) | LT2968520T (en) |
MX (2) | MX2015012709A (en) |
PL (1) | PL2968520T3 (en) |
PT (1) | PT2968520T (en) |
RS (1) | RS62304B1 (en) |
RU (2) | RU2721707C2 (en) |
SG (2) | SG11201507424WA (en) |
SI (1) | SI2968520T1 (en) |
WO (1) | WO2014159940A1 (en) |
ZA (1) | ZA201506658B (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
DK2968520T3 (en) | 2013-03-14 | 2021-08-09 | Macrogenics Inc | BISPECIFIC MOLECULES THAT ARE IMMUNORE ACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
UA116479C2 (en) | 2013-08-09 | 2018-03-26 | Макродженікс, Інк. | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |
MX2016005762A (en) | 2013-11-11 | 2016-08-19 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule containing modified antibody variable region. |
WO2016054101A1 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
US10344077B2 (en) | 2015-03-19 | 2019-07-09 | Duke University | HIV-1 neutralizing antibodies and uses thereof (V3 antibodies) |
CA2979708A1 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
WO2016149710A2 (en) | 2015-03-19 | 2016-09-22 | Duke University | Hiv-1 neutralizing antibodies and uses thereof |
US10450368B2 (en) | 2015-03-19 | 2019-10-22 | Duke University | HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies) |
WO2017081190A1 (en) * | 2015-11-13 | 2017-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
MX2018007089A (en) | 2015-12-14 | 2019-01-30 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof. |
JP2019517539A (en) | 2016-06-07 | 2019-06-24 | マクロジェニクス,インコーポレーテッド | Combination therapy |
US10772291B2 (en) | 2016-07-14 | 2020-09-15 | Rolane Christian Grinnell | Portable pet feeder and supply storage apparatus |
US11292839B2 (en) | 2016-08-13 | 2022-04-05 | Ubi Us Holdings, Llc | Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients |
EP3579848A4 (en) | 2017-02-08 | 2021-03-03 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
DK3582806T3 (en) | 2017-02-20 | 2023-09-11 | Dragonfly Therapeutics Inc | PROTEINS THAT BIND HER2, NKG2D AND CD16 |
AU2018224094A1 (en) | 2017-02-24 | 2019-09-19 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
CN108728464A (en) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | A kind of minicircle dna carrier and its preparation method and application of expression AntiHIV1 RT activity bispecific antibody |
CN108728465A (en) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | A kind of minicircle dna carrier and its preparation method and application of expression target cell-effector cell's bridge |
CN108728463A (en) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | A kind of minicircle dna carrier and its preparation method and application of expression IgG antibody |
KR102324568B1 (en) | 2017-06-21 | 2021-11-10 | 길리애드 사이언시즈, 인코포레이티드 | Multispecific antibodies targeting HIV gp120 and CD3 |
HUE057110T2 (en) * | 2017-07-14 | 2022-04-28 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
CL2020000098A1 (en) * | 2017-07-14 | 2020-05-29 | Immatics Biotechnologies Gmbh | Polypeptide molecule with enhanced dual specificity. |
CN109384848A (en) * | 2017-08-10 | 2019-02-26 | 深圳市雅臣智能生物工程有限公司 | Double targeting antibodies of anti-human papilloma virus (anti-HPV) and anti-CD humanization and combinations thereof, preparation method and application |
EP3665197A2 (en) * | 2017-08-11 | 2020-06-17 | H. Hoffnabb-La Roche Ag | Anti-cd8 antibodies and uses thereof |
EP3724231A4 (en) | 2017-12-12 | 2021-08-11 | MacroGenics, Inc. | Bispecific cd 16-binding molecules and their use in the treatment of disease |
BR112020016190A2 (en) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | ANTIBODY VARIABLE DOMAINS DIRECTING THE NKG2D RECEIVER |
AU2019222666A1 (en) | 2018-02-15 | 2020-09-03 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
EP3794027A4 (en) * | 2018-05-18 | 2022-02-09 | MacroGenics, Inc. | Optimized gp41-binding molecules and uses thereof |
CA3112788A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
CN109734810A (en) * | 2019-01-24 | 2019-05-10 | 深圳市雅臣智能生物工程有限公司 | Anti- African swine fever virus and CD dual-target pig source antibody, the preparation method and application |
DE102019121007A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigen binding proteins that specifically bind to MAGE-A |
US20240093158A1 (en) * | 2019-10-10 | 2024-03-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic viruses that express multi-specific immune cell engagers |
AU2020408707A1 (en) * | 2019-12-18 | 2022-08-11 | Janssen Biotech, Inc. | Materials and methods for in vivo biological targeting |
CN113088495A (en) * | 2020-01-09 | 2021-07-09 | 苏州方德门达新药开发有限公司 | Engineered T cells, their preparation and use |
CR20230101A (en) * | 2020-08-25 | 2023-04-28 | Gilead Sciences Inc | Multi-specific antigen binding molecules targeting hiv and methods of use |
TW202216754A (en) * | 2020-08-25 | 2022-05-01 | 美商賽特免疫治療公司 | Bispecific antibody car cell immunotherapy |
KR20230084561A (en) * | 2020-10-12 | 2023-06-13 | 그레펙스 인코포레이티드 | Antibody constructs targeting T cell responses to SARS-COV protein expressing cells, design and use thereof |
JP2023544890A (en) | 2020-10-13 | 2023-10-25 | ヤンセン バイオテツク,インコーポレーテツド | Bioengineered T cell-mediated immunity, materials and other methods for modulating differentiation antigen groups IV and/or VIII |
WO2022093694A1 (en) * | 2020-10-26 | 2022-05-05 | A2 Biotherapeutics, Inc. | Polypeptides targeting hpv peptide-mhc complexes and methods of use thereof |
WO2023227018A1 (en) * | 2022-05-25 | 2023-11-30 | 羿尊生物医药(浙江)有限公司 | Fusion protein targeting cell membrane receptor proteins and use thereof |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (en) | 1974-03-08 | 1982-06-04 | ||
US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4752601A (en) | 1983-08-12 | 1988-06-21 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin FC receptors |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5985599A (en) | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
ATE108068T1 (en) | 1987-09-23 | 1994-07-15 | Bristol Myers Squibb Co | ANTIBODY HETEROCONJUGATES FOR KILLING HIV-INFECTED CELLS. |
JP3095168B2 (en) | 1988-02-05 | 2000-10-03 | エル. モリソン,シェリー | Antibodies with domain-denaturing constants |
US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5576184A (en) | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
ATE159982T1 (en) | 1988-09-15 | 1997-11-15 | Univ Columbia | ANTIBODIES WITH MODIFIED CARBOHYDRATE CONTENT AND METHOD OF PRODUCTION AND USE |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
GB8916400D0 (en) | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5364930A (en) | 1990-10-16 | 1994-11-15 | Northwestern University | Synthetic C1q peptide fragments |
GB9105245D0 (en) | 1991-03-12 | 1991-04-24 | Lynxvale Ltd | Binding molecules |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
DE69433279T2 (en) | 1993-02-10 | 2004-07-15 | Unilever N.V. | INSULATION PROCESS USING IMMOBILIZED PROTEINS WITH SPECIFIC BINDING CAPACITIES |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
WO1995004069A1 (en) | 1993-07-30 | 1995-02-09 | Affymax Technologies N.V. | Biotinylation of proteins |
GB9316989D0 (en) | 1993-08-16 | 1993-09-29 | Lynxvale Ltd | Binding molecules |
JPH10500670A (en) | 1994-05-13 | 1998-01-20 | エクラゲン リミテッド | Improved peptide delivery or implications for peptide delivery |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
DE69731289D1 (en) | 1996-03-18 | 2004-11-25 | Univ Texas | IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
JP2001506967A (en) | 1996-08-02 | 2001-05-29 | ブリストル―マイヤーズ・スクイブ・カンパニー | Methods for suppressing immunoglobulin-induced toxicity as a result of the use of immunoglobulins in therapy and in vivo diagnosis |
US6025485A (en) | 1997-02-14 | 2000-02-15 | Arcaris, Inc. | Methods and compositions for peptide libraries displayed on light-emitting scaffolds |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
DE69840723D1 (en) | 1997-02-11 | 2009-05-20 | Immunomedics Inc | STIMULATING AN IMMUNE RESPONSE BY ANTIBODIES MARKED WITH THE ALPHA GALACTOSYLEPITOP |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
JP4213224B2 (en) * | 1997-05-02 | 2009-01-21 | ジェネンテック,インコーポレーテッド | Method for producing multispecific antibody having heteromultimer and common component |
DE19721700C1 (en) | 1997-05-23 | 1998-11-19 | Deutsches Krebsforsch | Mutant OKT3 antibody |
PL199659B1 (en) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Antibody-based fusion protein featured by prolonged residence in a cireculatory system and method of prolonging its residence time in a circulatory system |
US6455263B2 (en) | 1998-03-24 | 2002-09-24 | Rigel Pharmaceuticals, Inc. | Small molecule library screening using FACS |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
SE9802213D0 (en) | 1998-06-18 | 1998-06-18 | Amersham Pharm Biotech Ab | A method for the removal / purification of serum albumins and means for use in the method |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US7315786B2 (en) | 1998-10-16 | 2008-01-01 | Xencor | Protein design automation for protein libraries |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
PL209786B1 (en) | 1999-01-15 | 2011-10-31 | Genentech Inc | Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
DE19937264A1 (en) | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶ antibody constructs |
AU2001233277B2 (en) * | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
JP2004500108A (en) | 2000-03-24 | 2004-01-08 | マイクロメット アーゲー | Multifunctional polypeptide containing a binding site to an epitope of the NKG2D receptor complex |
EP1294904A1 (en) | 2000-06-30 | 2003-03-26 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Heterodimeric fusion proteins |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
EP2357187A1 (en) | 2000-12-12 | 2011-08-17 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
AU2002254683C1 (en) | 2001-04-18 | 2009-01-22 | Dyax Corp. | Binding molecules for Fc-region polypeptides |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
CA2462883A1 (en) | 2001-10-12 | 2003-04-17 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
CA2463931A1 (en) | 2001-10-16 | 2003-04-24 | The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
BR0213761A (en) | 2001-10-25 | 2005-04-12 | Genentech Inc | Compositions, pharmaceutical preparation, industrialized article, mammalian treatment method, host cell, method for producing a glycoprotein and use of the composition |
US20050142539A1 (en) | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
EP1354600A1 (en) | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
US20070274998A1 (en) | 2002-04-29 | 2007-11-29 | Genpatzz Pharmacogentetics Ag | Novel Bispecific Molecules For Use In Therapy And Diagnosis |
ATE483472T1 (en) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | CD16A BINDING PROTEINS AND USE IN THE TREATMENT OF IMMUNE DISEASES |
US20040071705A1 (en) | 2002-06-21 | 2004-04-15 | Dyax Corporation | Serum protein-associated target-specific ligands and identification method therefor |
US8187593B2 (en) | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8044180B2 (en) | 2002-08-14 | 2011-10-25 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8193318B2 (en) | 2002-08-14 | 2012-06-05 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
US20050260213A1 (en) | 2004-04-16 | 2005-11-24 | Scott Koenig | Fcgamma-RIIB-specific antibodies and methods of use thereof |
BRPI0314814C1 (en) | 2002-09-27 | 2021-07-27 | Xencor Inc | antibody comprising an fc variant |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2004062619A2 (en) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
DE10303664A1 (en) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Detection molecules for the treatment and detection of tumors |
JP5026072B2 (en) | 2003-07-01 | 2012-09-12 | イミューノメディクス、インコーポレイテッド | Multispecific carrier of bispecific antibody |
DE10346627A1 (en) | 2003-10-08 | 2005-05-19 | Weiss, Stefan, PD Dr. | Single-chain antibodies against the 37 kDa / 67 kDa laminin receptor as tools for the diagnosis and treatment of prion diseases and cancer, their production and use |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
EP2154157A3 (en) | 2004-01-12 | 2010-04-28 | Applied Molecular Evolution Inc. | FC region variants |
CA2563379A1 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
KR101297146B1 (en) | 2004-05-10 | 2013-08-21 | 마크로제닉스, 인크. | HUMANIZED FcγRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
US7432419B2 (en) | 2004-05-14 | 2008-10-07 | Los Alamos National Security, Llc | Compositions and methods for the treatment of Pierce's disease |
US7632924B2 (en) | 2004-06-18 | 2009-12-15 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
ES2426816T3 (en) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Fc regions variants |
US20080038280A1 (en) * | 2004-10-14 | 2008-02-14 | Government Of The United States Of America | A32 Monoclonal Antibody Fusion Proteins For Use As Hiv Inhibitors And Vaccines |
EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | Engineering fc antibody regions to confer effector function |
US20060193849A1 (en) | 2005-02-25 | 2006-08-31 | Antisoma Plc | Biological materials and uses thereof |
ES2546543T3 (en) | 2005-03-14 | 2015-09-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies against Hendra and Nipah viruses |
US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
DK1919503T3 (en) | 2005-08-10 | 2014-12-15 | Macrogenics Inc | Identification and preparation of antibodies with variant fc regions and methods of use thereof |
ES2616316T3 (en) * | 2005-10-11 | 2017-06-12 | Amgen Research (Munich) Gmbh | Compositions comprising specific antibodies for different species and uses thereof |
JP5427027B2 (en) * | 2006-05-03 | 2014-02-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト | CD40 agonist antibody / type I interferon synergistic adjuvant conjugates, conjugates comprising the same, and their use as therapeutics to enhance cellular immunity |
US7786270B2 (en) | 2006-05-26 | 2010-08-31 | Macrogenics, Inc. | Humanized FcγRIIB-specific antibodies and methods of use thereof |
AR065372A1 (en) | 2007-02-19 | 2009-06-03 | Smithkline Beecham Corp | PURINA DERIVATIVES |
CN107226864A (en) | 2007-06-21 | 2017-10-03 | 宏观基因有限公司 | Covalent diabodies and application thereof |
US20110212076A1 (en) | 2007-10-15 | 2011-09-01 | King's College London | Viral Therapeutic |
JP2011502163A (en) | 2007-10-31 | 2011-01-20 | ザ スクリプス リサーチ インスティテュート | Combination therapies to treat persistent viral infections |
WO2009117030A2 (en) | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
US20100040635A1 (en) | 2008-03-28 | 2010-02-18 | Sea Lane Biotechnologies | Neutralizing antibodies to influenza viruses |
US20100040601A1 (en) | 2008-06-10 | 2010-02-18 | Cantin Edouard M | Compositions and methods for treating herpes simplex virus infections and related diseases |
AU2009335798B2 (en) | 2008-12-19 | 2014-11-27 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US8211866B2 (en) | 2009-01-14 | 2012-07-03 | Children's Research Institute, Children's National Medical Center | Methods and compositions for treating HIV infection |
WO2010104836A1 (en) | 2009-03-09 | 2010-09-16 | Tvax Biomedical, Llc | Infectious disease cellular immunotherapy |
US20110033389A1 (en) | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
HUE035773T2 (en) | 2009-06-05 | 2018-05-28 | Ablynx Nv | Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
EP3916011A1 (en) | 2009-06-26 | 2021-12-01 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
KR101778317B1 (en) | 2009-08-13 | 2017-09-13 | 얀센 백신스 앤드 프리벤션 비.브이. | Antibodies against human respiratory syncytial virus(rsv) and methods of use |
RU2583298C2 (en) | 2009-10-07 | 2016-05-10 | Макродженикс, Инк. | POLYPEPTIDES CONTAINING Fc-SECTION THAT DISPLAY INCREASED EFFECTOR FUNCTION OWING TO VARYING FUCOSYLATION LEVEL AND THEIR APPLICATIONS |
US8999398B2 (en) | 2009-11-06 | 2015-04-07 | Transtarget Inc. | Polyclonal bispecific antibody compositions and method of use |
US8663950B2 (en) | 2010-01-11 | 2014-03-04 | Arizona Board Of Regents | Production of a monoclonal antibody therapeutic against west nile virus in plants |
WO2011133886A2 (en) * | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
CA2807127C (en) * | 2010-08-02 | 2019-02-12 | Leslie S. Johnson | Covalent diabodies and uses thereof |
CA3109036C (en) | 2010-08-31 | 2023-08-01 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
BR112013019499B1 (en) * | 2011-02-04 | 2023-01-10 | Genentech, Inc. | VARIANT HETERO-MULTIMERIC PROTEIN OR MODIFIED IGG ANTIBODY, METHOD FOR PRODUCING A VARIANT HETERO-MULTIMERIC PROTEIN OR MODIFIED IGG ANTIBODY, COMPOSITION, METHOD FOR PREPARING A HETERO-MULTIMERIC PROTEIN AND VARIANT HETERO-MULTIMERIC PROTEIN |
BR122016016837A2 (en) * | 2011-05-21 | 2019-08-27 | Macrogenics Inc | cd3 binding molecules; cd3 binding antibodies; pharmaceutical compositions; and uses of the cd3 binding molecule |
UA111612C2 (en) | 2011-05-21 | 2016-05-25 | Макродженікс, Інк. | DOMAINS WHICH ARE CONNECTED TO DEIMMUNIZED SERUM |
WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
US9879068B2 (en) | 2012-06-21 | 2018-01-30 | California Institute Of Technology | Antibodies targeting HIV escape mutants |
CA2886448A1 (en) | 2012-09-26 | 2014-04-03 | Duke University | Adcc-mediating antibodies, combinations and uses thereof |
DK2968520T3 (en) | 2013-03-14 | 2021-08-09 | Macrogenics Inc | BISPECIFIC MOLECULES THAT ARE IMMUNORE ACTIVE WITH IMMUNE EFFECTOR CELLS EXPRESSING AN ACTIVATING RECEPTOR |
-
2014
- 2014-03-13 DK DK14776214.0T patent/DK2968520T3/en active
- 2014-03-13 SI SI201431859T patent/SI2968520T1/en unknown
- 2014-03-13 WO PCT/US2014/025491 patent/WO2014159940A1/en active Application Filing
- 2014-03-13 RS RS20210957A patent/RS62304B1/en unknown
- 2014-03-13 SG SG11201507424WA patent/SG11201507424WA/en unknown
- 2014-03-13 CN CN202010439230.3A patent/CN111925437A/en active Pending
- 2014-03-13 HU HUE14776214A patent/HUE055845T2/en unknown
- 2014-03-13 CN CN201480025460.8A patent/CN105189561B/en not_active Expired - Fee Related
- 2014-03-13 AU AU2014244286A patent/AU2014244286B2/en not_active Ceased
- 2014-03-13 BR BR112015022790A patent/BR112015022790A8/en active Search and Examination
- 2014-03-13 RU RU2015143457A patent/RU2721707C2/en not_active Application Discontinuation
- 2014-03-13 PT PT147762140T patent/PT2968520T/en unknown
- 2014-03-13 US US14/775,041 patent/US9908938B2/en active Active
- 2014-03-13 JP JP2016501861A patent/JP6676521B2/en not_active Expired - Fee Related
- 2014-03-13 RU RU2020115527A patent/RU2020115527A/en unknown
- 2014-03-13 AP AP2015008740A patent/AP2015008740A0/en unknown
- 2014-03-13 LT LTEP14776214.0T patent/LT2968520T/en unknown
- 2014-03-13 ES ES14776214T patent/ES2882183T3/en active Active
- 2014-03-13 SG SG10201705245TA patent/SG10201705245TA/en unknown
- 2014-03-13 CA CA2906566A patent/CA2906566A1/en active Pending
- 2014-03-13 MX MX2015012709A patent/MX2015012709A/en unknown
- 2014-03-13 EP EP20217972.7A patent/EP3839044A1/en active Pending
- 2014-03-13 PL PL14776214T patent/PL2968520T3/en unknown
- 2014-03-13 EP EP14776214.0A patent/EP2968520B1/en active Active
-
2015
- 2015-09-09 ZA ZA2015/06658A patent/ZA201506658B/en unknown
- 2015-09-10 IL IL241487A patent/IL241487B/en active IP Right Grant
- 2015-09-11 MX MX2021000435A patent/MX2021000435A/en unknown
-
2016
- 2016-07-06 HK HK16107893.5A patent/HK1219876A1/en unknown
-
2018
- 2018-01-24 US US15/879,056 patent/US10730947B2/en active Active
-
2019
- 2019-02-08 AU AU2019200912A patent/AU2019200912B2/en not_active Ceased
- 2019-12-10 JP JP2019222992A patent/JP6979447B2/en active Active
-
2020
- 2020-03-29 IL IL273666A patent/IL273666B/en active IP Right Grant
- 2020-06-22 US US16/908,185 patent/US11421031B2/en active Active
-
2021
- 2021-07-27 HR HRP20211212TT patent/HRP20211212T1/en unknown
- 2021-08-11 CY CY20211100722T patent/CY1124570T1/en unknown
- 2021-09-22 JP JP2021154658A patent/JP2022000044A/en active Pending
-
2022
- 2022-07-14 US US17/812,492 patent/US20230167178A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1219876A1 (en) | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor | |
HRP20190502T1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
HK1222338A1 (en) | Cell receptors | |
HK1217958A1 (en) | Tetravalent bispecific antibodies | |
ZA201507790B (en) | Enhanced adoptive cell therapy | |
HK1221724A1 (en) | Cell receptors | |
EP2956481A4 (en) | Antigen-specific t cell redirectors | |
GB201322430D0 (en) | T cell receptors | |
HK1218647A1 (en) | Vasopressin-2 receptor agonists -2 | |
TWM475204U (en) | Tire-shaped luggage | |
AP2013006754A0 (en) | Pylon | |
GB201320573D0 (en) | T Cell |